When most Australians think about drug contamination in properties, they think exclusively about methamphetamine. That is understandable — meth is the most commonly detected illicit drug residue in Australian homes, and it is the only substance for which we have established residential guideline values (0.5 µg/100cm² under the enHealth guidelines). But after 24 years and over 5,000 property assessments, I can tell you with certainty: methamphetamine is not the only drug that contaminates properties, and it is not always the most dangerous one present.

The Meth-Only Blind Spot

The overwhelming majority of drug residue testing conducted in Australia tests for a single analyte: methamphetamine. There are practical reasons for this. Methamphetamine is Australia’s most widely used illicit stimulant. It produces significant surface contamination when smoked (the vapour condenses onto every surface in the room) and even more when manufactured. Single-analyte meth testing is also the cheapest analysis available — a straightforward immunoassay or LC-MS confirmation targeting one compound.

But this narrow focus creates a significant blind spot. A property may return a “clear” meth test while harbouring significant contamination from other substances — cocaine, MDMA, opiates, synthetic cannabinoids, or the increasingly prevalent fentanyl. If you only test for methamphetamine, you only find methamphetamine. The absence of meth does not mean the absence of drug contamination.

I have assessed properties where the methamphetamine results were below guideline levels, but multi-drug panel testing revealed substantial cocaine contamination, heroin residue on bathroom surfaces, or — in one particularly concerning case — fentanyl residue at levels that posed a genuine dermal absorption risk. These findings would have been completely missed by standard meth-only testing.

The Full Spectrum of Drug Residues

Cannabis and THC

Cannabis is Australia’s most commonly used illicit drug, yet cannabis residue testing is rarely requested. Heavy, prolonged cannabis smoking deposits tetrahydrocannabinol (THC) and other cannabinoid compounds on walls, ceilings, soft furnishings, and particularly carpet. The distinctive tar produced by cannabis smoke is chemically distinct from tobacco tar and creates a sticky, persistent residue that bonds strongly to porous surfaces.

While THC residue from smoking generally presents lower acute toxicity than methamphetamine surface contamination, it produces significant problems: persistent and pervasive odour that resists conventional cleaning, yellow-brown discolouration of painted surfaces, and degraded indoor air quality as residues off-gas over time. For landlords, the practical impact is significant — a property heavily contaminated with cannabis smoke residue may require repainting, carpet replacement, and HVAC cleaning to restore it to a habitable standard.

Cannabis cultivation, however, is an entirely different matter. The contamination risks from grow houses extend far beyond THC and are covered in detail in our companion article on cannabis grow house contamination.

Cocaine

Cocaine contamination in Australian properties has increased markedly over the past decade, reflecting increased availability and use. Unlike methamphetamine, which primarily contaminates through smoking vapour and manufacturing processes, cocaine contamination occurs through:

• Powder dispersal: Cutting, dividing, and handling cocaine powder releases fine particles that settle on nearby surfaces. Benzoyl ecgonine (cocaine’s primary metabolite) can be detected on surfaces surrounding preparation areas.
• Smoking crack cocaine: While less common in Australia than North America, crack cocaine smoking produces vapour-borne contamination similar to methamphetamine smoking.
• Contact transfer: Cocaine residue on hands transfers to door handles, light switches, tap handles, and other high-touch surfaces.

Cocaine surface residue degrades relatively quickly compared to methamphetamine — it has a shorter environmental half-life. However, in enclosed spaces with limited ventilation, significant residue can persist for weeks to months, particularly on smooth, non-porous surfaces.

MDMA (Ecstasy) and Related Amphetamines

MDMA (3,4-methylenedioxymethamphetamine) and its analogues — MDA, MDEA, and various novel psychoactive substances — contaminate properties primarily through powder handling, crushing tablets, and skin contact transfer. MDMA is not typically smoked, so vapour-borne contamination is rare. However, properties used for MDMA distribution or manufacturing can show substantial surface contamination.

MDMA manufacturing, while less common than methamphetamine manufacturing in Australia, uses precursor chemicals (safrole, PMK, piperonal) that produce their own contamination signatures. A competent forensic chemist can distinguish between a property where MDMA was merely used and one where it was manufactured, based on the specific chemical residues detected.

Heroin and Opiates

Heroin (diacetylmorphine) and other opiates contaminate properties through several pathways:

• Smoking (“chasing the dragon”): Heating heroin on foil and inhaling the vapour deposits morphine and its metabolites on nearby surfaces. This is the most common use method in Australia and produces measurable surface contamination.
• Injection preparation: Dissolved heroin splashes, spills, and residue from preparation surfaces. Bathroom and kitchen surfaces where injections are prepared can harbour both opiate residue and biological hazards (bloodborne pathogen risk).
• Powder handling: Similar to cocaine, heroin powder disperses during handling and division.

The health risk from opiate surface residue depends heavily on the specific compound. Morphine and heroin residues from traditional opiate use present moderate dermal absorption risks. The situation becomes dramatically more dangerous when synthetic opioids enter the picture.

Fentanyl and Synthetic Opioids

Fentanyl contamination has become an increasing concern in Australian law enforcement and emergency services, and it is beginning to appear in residential property assessments. Properties associated with fentanyl distribution, use, or even transit can retain surface contamination that poses dermal absorption risks, particularly to children and pets who have proportionally greater skin surface area relative to body mass and spend more time in direct contact with contaminated surfaces (crawling on floors, touching surfaces and then touching mouths).

Detection of fentanyl requires highly sensitive analytical methods. Standard immunoassay field-screening kits designed for methamphetamine will not detect fentanyl. Only laboratory-based LC-MS/MS (liquid chromatography-tandem mass spectrometry) analysis with appropriate calibration provides reliable detection and quantification of fentanyl and its analogues at toxicologically relevant concentrations.

GHB and Ketamine

Gamma-hydroxybutyrate (GHB) and ketamine contaminate properties through liquid spills and powder handling respectively. GHB is hygroscopic (absorbs moisture from the air), making surface residue detection challenging because it deliquesces and can be washed away or absorbed into porous surfaces. Ketamine powder, like cocaine, disperses during handling and settles on surrounding surfaces.

Neither substance typically produces the extensive surface contamination seen with smoked drugs like methamphetamine. However, properties used for manufacturing or bulk distribution of either substance can show significant contamination, often accompanied by other chemical residues from the manufacturing process.

How Different Drugs Contaminate Differently

Understanding how a drug enters the environment is critical to understanding where to sample and what levels to expect. The contamination pathway determines the contamination pattern.

• Smoking/vaporisation (meth, heroin, crack cocaine, cannabis): Produces airborne contamination that settles on all surfaces in the room — walls, ceilings, furniture, carpets, and HVAC systems. Contamination is relatively uniform throughout the space.
• Powder handling (cocaine, MDMA, ketamine, fentanyl): Produces localised contamination concentrated around preparation surfaces — kitchen benchtops, bathroom vanities, coffee tables, mirrors. Contamination gradient decreases rapidly with distance from the preparation area.
• Injection preparation (heroin, methamphetamine): Produces highly localised contamination on preparation surfaces, often in bathrooms. Additional biological contamination risk from blood and body fluid exposure.
• Manufacturing (meth, MDMA, GHB): Produces the most extensive and severe contamination. Chemical precursors, reagents, solvents, and waste products contaminate surfaces, soils, drains, and building materials. This is a fundamentally different contamination scenario from drug use.

When Multi-Drug Testing Is Warranted

Based on my experience assessing thousands of properties, I recommend multi-drug panel testing in the following situations:

• Deceased estates: Where the occupant’s drug use history is unknown and the property needs to be cleared for sale or new tenancy.
• Rental turnovers following eviction: Particularly where the eviction involved drug-related antisocial behaviour, police attendance, or complaints from neighbours.
• Properties with law enforcement history: Former drug houses, known distribution points, or properties where warrants have been executed.
• Former share accommodation or party houses: Where multiple occupants may have used various substances over extended periods.
• Properties exhibiting suspicious indicators: Unusual chemical odours, unexplained staining, modified ventilation, evidence of smoking paraphernalia, or discarded drug packaging.
• Pre-purchase assessments with risk indicators: Neighbour reports, police records associated with the address, or property history suggesting drug involvement.

Laboratory Analysis Methods

Multi-drug panel testing requires significantly more sophisticated laboratory analysis than single-analyte methamphetamine testing. The gold standard method is LC-MS/MS (liquid chromatography-tandem mass spectrometry), which provides:

• Multi-analyte detection: A single sample can be simultaneously screened for 20-40+ substances including methamphetamine, amphetamine, MDMA, cocaine, benzoyl ecgonine, morphine, codeine, fentanyl, THC, and various synthetic analogues.
• High sensitivity: Detection limits in the nanogram range, critical for substances like fentanyl where even trace quantities are toxicologically significant.
• Specificity: Mass spectrometric confirmation eliminates false positives that plague immunoassay screening methods.
• Quantification: Accurate measurement of detected substances, enabling risk-based assessment of contamination levels.

All our multi-drug panel analyses are performed by independent NATA-accredited laboratories using validated methods. This ensures results are defensible, reproducible, and accepted by courts, insurers, and regulatory bodies.

The Regulatory Gap

Australia has established residential guideline values only for methamphetamine — the 0.5 µg/100cm² threshold published in the enHealth Guidance on the Investigation and Assessment of Methamphetamine Residue in Residential Settings. No equivalent guidelines exist for cocaine, MDMA, heroin, fentanyl, or any other illicit drug residue.

This represents a significant gap in the regulatory framework. In the absence of specific Australian guidelines, we apply risk-based assessment principles referencing:

• International guidelines where they exist (US EPA, Health Canada)
• Toxicological reference data for individual substances
• Occupational exposure limits adapted for residential scenarios
• Published literature on dermal absorption rates and bioavailability

Cost Comparison: Single vs Multi-Drug Testing

The cost difference between meth-only and multi-drug panel testing is less dramatic than most people expect. The majority of assessment cost lies in the site visit, sample collection, chain of custody documentation, and reporting — all of which remain identical regardless of what the laboratory analyses for. The incremental cost is purely the additional laboratory analysis.

A multi-drug panel analysis using LC-MS/MS typically costs 2-3 times more per sample than a single-analyte methamphetamine confirmation. For a standard residential assessment with 8-12 sample points, the total additional cost for multi-drug testing represents a modest increase for substantially more comprehensive information about the property’s contamination status.

Consider the alternative: paying for a meth-only assessment, receiving clear results, moving your family in, and later discovering that the property was used for cocaine distribution or fentanyl handling. The cost of retrospective testing, remediation, and potential health consequences far exceeds the incremental cost of comprehensive testing upfront.

Test Australia’s Comprehensive Drug Residue Service

Our comprehensive drug residue testing service goes beyond methamphetamine to provide a complete picture of a property’s contamination profile. Every assessment includes:

• Expert site assessment: Visual inspection by a qualified Chartered Chemist to identify contamination indicators and determine appropriate sampling strategy.
• Targeted surface sampling: Using NIOSH-compliant methodology, sampling high-risk surfaces based on the specific drug contamination pathways identified during assessment.
• Multi-drug panel analysis: LC-MS/MS analysis at an independent NATA-accredited laboratory covering methamphetamine, amphetamine, MDMA, cocaine, opiates (morphine, codeine, heroin metabolites), fentanyl, THC, and additional substances as indicated.
• Expert interpretation: Results interpreted in context by a forensic chemist who understands the toxicological significance of each substance, the contamination pathway, and the implications for occupant health.
• Comprehensive reporting: A forensically defensible report documenting methodology, results, risk assessment, and recommendations — suitable for legal, insurance, and regulatory purposes.

Our independence from remediation, cleaning, and laboratory companies ensures our assessments are objective. We identify what is there, explain what it means, and recommend appropriate responses — without any financial incentive to inflate findings. To discuss comprehensive drug residue testing for your property, contact us for a detailed consultation.